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Macroautophagy, a homeostatic process that 
shuttles cytoplasmic constituents into 
endosomal and lysosomal compartments, has 
recently been shown to deliver antigens for 
presentation on major histocompatibility 
complex (MHC) class II molecules. Skeletal 
muscle fibers show a high level of 
constitutive macroautophagy and express 
MHC class II molecules upon immune 
activation. We found that tumor necrosis 
factor-alpha (TNF-α), a monokine over-
expressed in inflammatory myopathies, led 
to a marked upregulation of 
macroautophagy in skeletal myocytes. 
Furthermore, TNF-α  augmented surface 
expression of MHC class II molecules in 
interferon-gamma (IFN-γ) treated 
myoblasts. The synergistic effect of TNF-α  
and IFN-γ  on the induction of MHC class II 
surface expression was not reflected by 
higher intracellular human leukocyte 
antigen (HLA)-DR levels and was reversed 
by macroautophagy inhibition, suggesting 
that TNF-α  facilitates antigen processing via 
macroautophay for more efficient MHC 
class II loading. Muscle biopsies from 
patients with sporadic inclusion body 
myositis, a well-defined myopathy with 
chronic inflammation, showed that over 
twenty percent of fibers that contained 
autophagosomes co-stained for MHC class II 
molecules and that more than forty percent 
of double–positive muscle fibers had contact 
to CD4+ and CD8+ immune cells. These 
findings establish a mechanism through 
which TNF-α  regulates both 
macroautophagy and MHC class II 
expression and suggest that 
macroautophagy-mediated antigen-
presentation contributes to the 
immunological environment of the inflamed 
human skeletal muscle. 
 
Introduction 
Autophagy is a homeostatic process that 
enables eukaryotic cells to deliver cytoplasmic 
constituents for lysosomal degradation, for 
example in to recycle nutrients for survival 
during starvation. In addition to this original 
function, autophagy has emerged as a key 
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mechanism in orchestrating innate and adaptive 
immune responses. During macroautophagy, 
the major route of degradation of cytoplasmic 
constituents, proteins and organelles are 
sequestered inside double-membrane vesicles 
(autophagosomes) that fuse with lysosomes/late 
endosomes. In the fusion vesicles, often 
multivesicular and multilamellar amphisomes, 
the captured material is degraded and antigenic 
fragments are loaded onto major 
histocompatibility complex (MHC) class II 
molecules for presentation to CD4+ T cells. In 
turn, innate and adaptive immune signals are 
capable of regulating macroautophagy via 
cytokine secretion and cell contact dependent 
mechanisms (1) (2) (3).  
 
In vivo analysis of macroautophagy in 
transgenic mice expressing the GFP-coupled 
specific autophagosome marker light chain 3 
(LC3), one mammalian homologue of yeast 
autophagy-related gene 8 (Atg8), demonstrated 
that the regulation of macroautophagy is organ-
dependent and that some tissues produce LC3–
positive autophagosomes even in the absence of 
nutrient starvation. Such constitutive 
autophagosomal activity has been observed in 
metabolically active tissues such as liver, 
thymus, and skeletal muscle (4).  
 
Skeletal myocytes are facultative antigen 
presenting cells and they actively participate in 
local immune reactions (5) (6), which develop 
spontaneously during the course of autoimmune 
and infectious muscle diseases (7) or can be 
induced by immunotherapeutic gene transfer 
into muscle (8). Upregulation of 
macroautophagy and lysosomal genes has been 
documented at the transcript and protein level 
in different settings in myopathies associated 
with immune cell infiltration (9) (10) (11) (12) 
(13). We previously showed that muscle fibers 
of patients with sporadic inclusion body 
myositis (sIBM), the most common acquired 
skeletal muscle disease in patients above the 
age of 50 years, show increased frequencies of 
autophagosomes in degenerating fibers 
compared to non-myopathic muscle or non-
vacuolated myopathic controls and that 
intracellular amyloid precursor protein 
(APP)/beta-amyloid colocalized with 
autophagosomal compartments (11) (10). 
Notably, colocalization of APP/beta-amyloid 
and LC3 was associated with upregulation of 
MHC class II molecules as well as CD4+ and 
CD8+ immune cell infiltration. The mechanisms 
that regulate macroautophagy and MHC 
expression in the immunological environment 
of the skeletal muscle are not well understood. 
We investigated immune-mediated 
macroautophagy regulation and MHC 
expression in primary human muscle cells and 
in skeletal muscle biospsies from patients with 
sIBM.  
 
 
Materials and Methods  
 
Patients. Under Institutional Review Board 
(IRB)-approved protocols, muscle biopsies 
were used from five patients with sIBM, who 
fulfilled the typical clinical and histopathologic 
criteria. 
 
Cell culture. All cell lines used in this study 
were routinely cultured in DMEM with 10% 
FCS, 2 mM glutamine, 110 microgram/ml 
sodium pyruvate, and 2 microgram/ml 
gentamycin. CCL136 cells were purchased 
from ATCC (Manassas, VA), HaCat cells were 
a kind gift from Dr. Rajiv Khanna (Brisbane, 
Australia), and MDAMC cells were a kind gift 
from Dr. Irene Joab (Paris, France). LC3 fusion 
constructs and stable transfectants were 
generated as described previously (14). Primary 
human skeletal muscle cells from healthy 
donors were purchased from PromoCell 
(Heidelberg, Germany) and cultured as well as 
differentiated into myotubes according to the 
provider’s recommendations. T cells, 
monocytes and dendritic cells (DCs) were 
prepared from PBMCs isolated from leukocyte 
concentrates (buffy coats) from the New York 
Blood Center. Positive selection for T cells and 
monocytes/macrophages was performed with 
anti-CD3 and anti-CD14 MicroBeads from 
Miltenyi Biotec, respectively. 1x106 T cells 
were cultured in the presence of PHA (1ug/ml) 
for 48 hours. DCs were generated from CD14-
positive cells in RPMI-1640 + 1% single-donor 
plasma + glutamine + gentamycin. 
Recombinant human IL-4 (rhIL-4, 500 U/ml) 
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and rhGM-CSF (1000 U/ml) were added on day 
0, 2, and 4. For maturation, floating immature 
DCs were transferred to new plates on day 5, 
and half of the medium was replaced with fresh 
medium containing the TLR3 agonist polyI:C 
(25ug/ml). IL-4 was obtained from Peprotech 
(Rocky Hill, NJ, USA) and GM-CSF from 
Immunex (Seattle, WA). 
 
atg12-specific RNA interference. The 
following 21-nt siRNA oligonucleotides were 
used: atg12 sense: 5‘-
UCAACUUGCUACUACAUGAUdT; atg12 
antisense: 5‘-
UCAUGUAGUAGCAAGUUGAUdT (nt. 687–
705 of NM_004707). siRNA duplexes were 
delivered by transfection with lipofectamine 
2000 (Invitrogen) at 30 pmol siRNA + 1.5 
microliter lipofectamine/well in a 24-well 
format, and effect of RNA silencing was 
analyzed after 2–3 days. 
 
Antibodies. The LC3 antiserum was generated 
by immunizing two rabbits with the N-terminal 
peptide LC31-15 (MPSEKTFKQRRTFEQR) 
conjugated to KLH carrier protein (Cocalico 
Biologicals, Reamstown, PA). Animals were 
boosted 5 times (2, 3, 7, 11, and 15 weeks after 
initial inoculation) and then sacrificed to obtain 
terminal bleeds. Antiserum collected from one 
rabbit showed good LC3 reactivity by ELISA 
and in Western blots, and was used at a dilution 
of 1:2000 for Western blots. A polyclonal rabbit 
anti-human APP antibody recognizing an 
epitope within the C-terminus of the protein 
(AHP663, Serotec, Oxford, UK) was used at a 
1:100 dilution. Anti-β-actin antibody was 
purchased from Sigma-Aldrich (St. Louis, MO, 
USA). Immunoblots were performed as 
described previously (14).  For 
immunocytochemistry, we used a monoclonal 
mouse anti-human LC3-specifc antibody 
(Nanotools, Teningen, Germany). Secondary 
antibodies were Rhodamine-Red-X-(RRX)-
conjugated donkey anti-mouse IgGs (Jackson 
ImmunoResearch, West Grove, PA, USA). 
FITC-conjugated TNF-R1 and PE-conjugated 
TNF-R2 antibodies and their respective isotype 
controls were purchased form R&D Systems 
(Minneapolis, MN, USA). PE-conjugated HLA-
DR and FITC-conjugated HLA-A, -B, -C and 
their respective isotype controls were purchased 
from BD Bioscience (San Jose, CA, USA). For 
immunohistochemistry, LC3 was detected by 
the rabbit polyclonal antiserum (see above) at 
1:1000 dilution; for surface MHC class II (DP, 
DQ, DR), a mouse monoclonal antibody (clone 
TDR31.1 from Ancell, Bayport, MN, USA) was 
used at 10µg/ml; CD3 was detected by a rat 
monoclonal antibody (clone CD-12 from 
Serotec, Düsseldorf, Germany) at 5µg/ml; CD4 
was labeled by a mouse monoclonal antibody 
(clone 34930 from R&D Systems, MN, USA) 
at 2µg/ml; CD8 was stained using a rat 
monoclonal antibody (clone YTC 182.20 from 
AbD Serotec, Düsseldorf, Germany) at 5µg/ml. 
 
Immunocytochemistry and confocal 
microscopy. Cells were grown on microscopy 
cover glasses in 24-well plates overnight and 
fixed in 3% paraformaldehyde in PBS for 15 
min and permeabilized in 0.1% Triton X-100 in 
PBS for 5 min. Cells were blocked for 30 min 
in blocking buffer (from Perkin Elmer's TSA 
kit) + 0.1% saponin. Primary and secondary 
antibodies were applied in blocking buffer + 
0.1% saponin + 5% normal donkey serum for 
30–60 min, followed by three 5 min washes in 
PBS + 0.1% saponin. Finally, cells were stained 
with DAPI nucleic acid stain (0.5  g/ml, 
Invitrogen-Molecular Probes) for 1 min and 
cover glasses were mounted onto microscope 
slides with Prolong Gold antifade reagent 
(Invitrogen-Molecular Probes). All steps were 
carried out at room temperature. Cells were 
analyzed with an inverted LSM 510 laser 
scanning confocal microscope (Zeiss Axiovert 
200) with a 63 or 100×/1.4 N.A. oil immersion 
lens with a pinhole diameter of 1 Airy unit. 
Pictures were taken with the LSM 510 confocal 
software (Zeiss).  
 
Immunohistochemistry and fluorescence 
microscopy. For immunohistochemistry, 5µm 
frozen sections of muscle biopsy specimens 
were fixed in 4% paraformaldehyde (LC3) or 
ice cold acetone (all other antibodies) for 10 
min. Unspecific binding was reduced by 30 
min. incubation with 5% bovine serum albumin 
(BSA) and 3% goat serum (all from Jackson 
ImmunoResearch, West Grove, PA, USA) in 
PBS. All primary and secondary reagents were 
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diluted in 1% BSA. Double labeling for LC3 
and MHC class II as well as for CD3 and CD4 
was followed by secondary goat anti-rabbit 
IgG-Alexa 594 or anti-mouse IgG-Alexa 488, 
respectively (Molecular Probes/Invitrogen, 
Carlsbad, CA, USA). Nuclear counterstaining 
was performed by DAPI, followed by mounting 
in Fluoromount G (Electron Microscopy 
Sciences, Hatfield, PA, USA). 
Immunofluorescent microscopy and digital 
photography was performed on a Zeiss 
Axiophot microscope (Zeiss, Göttingen, 
Germany), using appropriate filters for green 
(488nm), red (594 nm) and blue (350 nm) 
fluorescence and a cooled CCD digital camera 
(Retiga 1300, Qimaging, Burnaby, BC, Canada) 
using the Qcapture software. For quantitative 
analysis of double-labeling of CD3 and CD4, 5 
inflammatory fields with a mean of 249 cells 
were manually counted in 10 muscle biopsies of 
patients with sIBM. 
Flow cytometry. Primary human myoblasts or 
CCL136 cells were harvested from tissue 
culture plates and washed once in PBS, either 
permeabilized in 0.5% saponin for 10 minutes 
at room temperature or left non-permeabilized, 
and stained with the directly fluorochrome-
labeled antibodies PE-conjugated HLA-DR and 
FITC-conjugated HLA-A, -B, -C and their 
respective isotype controls (BD Bioscience, San 
Jose, CA, USA) for 30 minutes at 4°C. The 
cells were washed once with PBS and 
resuspended in 200 µl FACS buffer prior to 
FACS analysis. The samples were measured on 
a BD LSR II flow cytometer (BD Biosciences, 
San Jose, CA, USA). Gating and calculations 
for precursor frequencies were performed with 
FlowJo software (Tree Star, Ashland, OR, 
USA).   
Luminex assay. Cell supernatants from DC and 
T cell cultures were analyzed for 20 cytokines 
and chemokines using the Protein Multiplex 
Immunoassay kit (Biosource International, 
Invitrogen, Carlsbad, CA, USA) as per the 
manufacturer's protocol. In brief, Multiplex 
beads were vortexed and sonicated for 30 s, and 
25 µl was added to each well and washed two 
times with wash buffer. The samples were 
diluted 1:2 with assay diluent and loaded onto a 
Multiscreen BV 96-well filter plate with 50 µl 
of incubation buffer already added to each well. 
Serial dilutions of cytokine standards were 
prepared in parallel and added to the plate. 
Samples were then incubated on a plate shaker 
at 600 rpm in the dark at room temperature for 2 
h. The plate was applied to a Multiscreen 
Vacuum Manifold (Millipore) and washed 
twice with 200 µl of wash buffer. 100 µl of 
biotinylated anti–human Multi-Cytokine 
Reporter was added to each well. The plate was 
incubated on a plate shaker at 600 rpm in the 
dark at room temperature for 1 h. The plate was 
applied to a Multiscreen Vacuum Manifold 
(Millipore) and washed twice with 200 µl of 
wash buffer. Streptavidin-phycoerythrin was 
diluted 1:10 in wash buffer, and 100 µl was 
added directly to each well. The plate was 
incubated on a plate shaker at 600 rpm in the 
dark at room temperature for 30 min. The plate 
was then applied to the vacuum manifold, 
washed twice, and each well was resuspended 
in 100 µl wash buffer and shaken for 1 min. The 
assay plate was then transferred to the Bio-Plex 
Luminex 100 XYP instrument for analysis. 
Cytokine concentrations were calculated using 
Bio-Plex Manager 3.0 software with a 5-
parameter curve-fitting algorithm applied for 
standard curve calculations. 
 
DNA fragmentation. Apoptotic DNA 
fragmentation was assessed as described 
previously (15) (16). Briefly, cells were fixed 
by adding of 70% (v/v) cold ethanol on ice, 
washed, and stained with TO-PRO-3 as DNA 
intercalating agent for 1 hour. Hypodiploid and 
diploid DNA peaks were quantified by flow 
cytometry. 
 
Statistics. Statistical analyses were performed 
using commercial software (PRISM 4, 
GraphPad Software, San Diego, CA). The 
paired t-test was used to compare MHC 
expression levels and specific DNA 
fragmentation in cytokine-stimulated muscle 
cell.  
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Results  
 
1. Macroautophagy is a constitutively active 
process in human skeletal muscle cells 
To quantify macroautophagy, we made use of 
the specific autophagosome marker LC3. LC3 
is a ubiquitin-like protein that is covalently 
coupled via its C terminus to a phospholipid in 
the newly forming inner and outer 
autophagosomal membranes and thus is 
specifically incorporated into autophagosomes 
(17). After fusion of autophagosomes with 
endosomes or lysosomes, intraluminal LC3 is 
rapidly degraded by lysosomal proteases. The 
more autophagosomes that are formed, the 
more LC3 is degraded in autolysosomes, and 
therefore, lysosomal turnover of LC3 is a good 
measure for macroautophagic activity (18). To 
visualize the lysosomal turnover of LC3 in 
human skeletal muscle cells by fluorescence 
microscopy, we transduced a human skeletal 
muscle cell line (CCL136) with a lentiviral 
GFP-LC3 fusion construct (14). GFP-LC3-
transfected cells were treated with the 
lysosomal acidification inhibitor chloroquine 
(CQ) to block lysosomal proteolysis and 
thereby to visualize the accumulation of GFP-
LC3 in autolysosomes.  
 
In the steady state (no CQ), only a small 
fraction of CCL136 cells had GFP-LC3-
positive autophagosomes (Figure 1A). 
However, GFP-LC3 strongly accumulated in 
cytosolic vesicles after 10 hr of CQ treatment 
(Figure 1A, right), suggesting that large 
numbers of GFP-LC3-labeled autophagosomes 
had formed and fused with lysosomes/late 
endosomes for GFP-LC3 degradation during 
the 10 hour observation period. The 
accumulation of GFP-LC3+ vesicles upon CQ 
treatment was dependent on macroautophagy, 
because siRNA-mediated silencing of atg12, a 
gene essential for autophagosome formation, 
abrogated accumulation of these vesicles 
(Figure 1B). Similar to CCL136 cells, primary 
human myoblasts showed a substantial level of 
constitutive macroautophagy and a marked 
accumulation of LC3+ vesicular compartments 
upon CQ treatment (Figure 1C). 
 
Autophagosome-associated LC3 (called LC3-
II) and free cytosolic LC3 (called LC3-I) can be 
distinguished by their apparent molecular 
weights in SDS-PAGE gel electrophoresis (16 
and 18 kDa, respectively) and thus can be 
quantified separately in anti-LC3 immunoblots 
(14,17). CCL136 muscle cells were cultured in 
the presence or absence of the lysosomal 
protease inhibitor CQ for 10 hr, and 
accumulation of LC3-II was quantified by 
immunoblotting. Autophagosome-associated 
LC3-II strongly accumulated upon CQ 
treatment (Figure 1D), demonstrating that LC3-
II-labeled autophagosomes were constitutively 
degraded in endosomes and/or lysosomes over 
the course of 10 hr. In addition, inhibition of the 
mammalian target of rapamycin (mTOR) by 
rapamycin resulted in a substantial increase in 
LC3-II expression in both CQ-treated and 
untreated cells (Figure 1D). Altogether, these 
experiments confirm that macroautophagy is a 
constitutively active process in human skeletal 
muscle cells under nutrient-rich conditions. 
 
2. TNF-α  selectively upregulates 
macroautophagy in skeletal myocytes  
T cells and myeloid dendritic cells (DCs) are 
the main component of inflammatory infiltrates 
in most immune-mediated skeletal muscle 
diseases (19). To identify immune factors that 
stimulate macroautophagy in skeletal myocytes, 
we exposed CCL136 muscle cells to 
supernatants derived from mitogen-activated 
polyclonal T cells and mature monocyte-
derived DCs. As shown in Fig. 2A, 
accumulation of LC3-II was observed after 
treatment with DC-derived supernatants only. 
We next quantified a set of 20 soluble 
inflammatory molecules in both DC- and T 
cell-derived supernatants via luminex (Figure 
2B). Cytokines that were detected in higher 
concentrations in DC-derived compared to T 
cell supernatants included: interleukin (IL)-12, 
IL-15, IL-6, GM-CSF and TNF-α (Figure 2B). 
These candidates together with IFN-γ as a 
classical proinflammatory cytokine produced 
by cytotoxic T cells were tested for their ability 
to induce LC3-II accumulation in CCL136 
muscle cells after 24 hr by western blotting. 
Each cytokine was tested at least 3 times at a 
concentration quantified in stimulatory DC-
 at SM
AC Consortium
 - University of Zürich, on M
arch 12, 2011
w
w
w
.jbc.org
D
ow
nloaded from
 
  Keller et al., page 6 
derived supernatants by luminex as well as at a 
1 log higher concentration (Table 1). Among all 
10 candidates tested, only TNF-α showed a 
consistent effect on LC3-II accumulation. 
Notably, neither IFN-γ nor IP-10 as a 
downstream molecule induced by IFN-γ 
augmented LC3-II expression in CCL136 
skeletal muscle cells (Figure 2A, left panel). In 
contrast, the TNF-α induced increase in LC3-II 
expression was present in both CQ treated and 
untreated cells and was detectable at TNF-α 
concentrations as low as 0.05 ng/ml (Figure 3A, 
middle panel).  
 
We noticed that TNF-α induced upregulation of 
macroautophagy was not ubiquitously observed 
in other cell lines. Although the MDAMC 
breast carcinoma cell line was susceptible to 
TNF-α mediated macroautophagy regulation 
(not shown), we could not detect any increase 
in LC3-II accumulation in the human 
keratinocyte cell line HaCat following TNF-α 
treatment (Figure 3A, right panel). In contrast, 
TNF-α induced augmentation of 
autophagosome formation was confirmed by 
immunocytochemistry in CCL136 muscle cells 
as well as in primary human myoblasts (Figure 
3B). 
  
These data indicate that human primary skeletal 
muscle cells are susceptible to cytokine-
mediated macroautophagy regulation. Among 
all monokines, lymphokines and chemokines 
tested, we found that the induction of 
macroautophagy in skeletal myocytes is 
primarily mediated by TNF-α. 
 
3. TNF-α  regulates MHC expression in IFN-
γ  treated primary myocytes  
Cultured human myoblasts constitutively 
express classical human MHC class I antigens 
(i.e. HLA-A, -B and –C), but lack MHC class II 
expression. However, MHC class II expression 
can be induced and MHC class I expression can 
be augmented in vitro by proinflammatory 
cytokines such as IFN-γ (5) (6) or in vivo as 
observed in inflammatory myopathies (20). 
Thus, activated human muscle cells are 
equipped with all major constituents necessary 
for MHC II antigen processing and they can 
present exogenous as well as endogenous 
antigens leading to the stimulation of antigen-
specific CD4+ T cells (21) (22) (23) (24).  
 
To investigate the effect of TNF-α on MHC 
regulation in cultured human myoblasts, we 
exposed primary muscle cell cultures to IFN-γ, 
TNF-α or both cytokines simultaneously and 
quantified MHC surface expression by flow 
cytometry. As expected, human myoblasts 
lacked constitutive MHC class II expression 
(HLA-DR), whereas MHC class I molecules 
(HLA-A, -B, and -C) were detectable at low 
levels in untreated cultures (Figure 4). Exposure 
to TNF-α alone did not show any statistically 
significant effect on both MHC class I and 
MHC class II surface levels, although we 
noticed that expression levels of HLA-A, -B, 
and -C molecules were slightly higher upon 
TNF-α. In line with previous data, TNF-α also 
showed a synergistic effect on MHC class I 
expression (8). IFN-γ strongly induced both 
MHC class I and MHC class II expression. 
Notably, addition of TNF-α to myoblasts 
exposed to IFN-γ significantly augmented 
MHC class II surface expression even though 
TNF-α alone had no effect on HLA-DR 
expression levels. The additive effect of TNF-α 
on MHC class II levels was not detectable in 
HaCat cells (Figure 4B), which upregulated 
MHC class II surface expression only upon 
IFN-γ. 
 
To investigate the hypothesis that TNF-α 
mediated upregulation of macroautophagy 
contributes to increased MHC class II surface 
expression levels in IFN-γ treated myoblasts, 
we next performed titration experiments which 
included concentrations of TNF-α that were 
sufficient to induce autophagosome formation 
in skeletal myocytes. As shown in Suppl. 
Figure 1, an additive effect of TNF-α was 
detectable at 50 ng/ml for MHC class I 
expression and at 5 ng/ml for MHC class II 
expression. Furthermore, we addressed whether 
TNF-α augments HLA-DR synthesis or 
affected intracellular versus surface HLA-DR 
compartimentalization in myocytes exposed to 
IFN-γ. To this end, we compared MHC class II 
expression levels in permeabilized and non-
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permeabilized myoblasts following 48 hours of 
cytokine treatment. As shown in Figure 5, the 
synergistic effect of TNF-α on MHC class II 
expression was lost following permeabilization 
(Fig. 5A), indicating that TNF-α, unlike IFN-γ, 
does not induce de novo HLA-DR synthesis but 
regulates MHC class II expression via 
translocation of HLA-DR from intracellular 
compartments to the cell surface. Since we 
found primary human myoblasts resistant to 
inhibition of autophagy by siRNA (data not 
shown), we inhibited macroautophagy by 
addition of 3-methyladenine (MA), which 
abolished the additive effect of TNF-α on IFN-
γ-induced upregulation of MHC class II surface 
expression in myoblasts (Fig. 5B). 
 
Altogether, these data show that TNF-α 
regulates MHC class I and class II expression in 
IFN-γ activated myoblasts. Moreover, they 
suggest that TNF-α increases HLA-DR surface 
expression via upregulation of autophagosome 
formation, possibly via delivery of 
autophagosome content to MHC class II 
compartments (MIIC) for efficient MHC class 
II loading and release of HLA-DR molecules to 
the cell surface.  
 
4. Resistance of skeletal muscle cells to TNF-
α  induced cell death 
Since macroautophagy has been implicated in 
protection from cell death (25) (26), we 
additionally determined whether human skeletal 
muscle cells are susceptible to receptor-
mediated apoptosis following TNF-α 
stimulation. TNF receptor (TNF-R) 1 and TNF-
R2 are expressed on the surface of CCL136 
muscle cells (Figure 6A) and primary human 
myoblasts (not shown) (27) (28). In most cell 
types, TNF-R1 only signals for cell death when 
the survival pathway is blocked, e.g. by protein 
synthesis inhibition (29). Therefore, we treated 
skeletal muscle cells with increasing 
concentrations of TNF-α in the presence and 
absence of the protein synthesis inhibitor 
cycloheximide (CHX; 1 µg/ml). Apoptotic cell 
death was analyzed after 24 hours by 
quantifying TO-PRO-3 permeability and 
specific DNA fragmentation in hypodiploid 
cells (15) (16). As depicted in Figure 6B, 
CCL136 skeletal muscle cells were completely 
resistant to TNF-α treatment alone, but showed 
a dose-dependent induction of cell death in the 
presence of TNF-α and CHX. CHX alone did 
not induce cell death at a concentration of 3 
µg/ml or lower. CHX-dependent cell death 
induction was observed in both CCL136 muscle 
cells and primary human myoblasts (not 
shown), indicating that TNF-α requires protein 
synthesis inhibition to induce apoptotic cell 
death in human myocytes. We additionally 
determined whether loss of macroautophagy 
function due to atg12-specific RNA 
interference or gain of macroautophagy 
function by mTOR inhibition due to rapamycin 
treatment interferes with the susceptibility for 
TNF-α mediated cell death. Neither atg12-
specific RNA silencing in CCL136 muscle cells 
nor rapamycin showed an effect on the 
susceptibility towards TNF-α induced apoptosis 
(Fig. 6C, D). 
 
Thus, although macroautophagy can be induced 
by TNF-α in skeletal muscle cells, these cells 
are resistant to TNF-R mediated cell death and 
macroautophagic regulation thereof. 
 
5. Muscle fibers from patients with sIBM 
show colocalization of autophagosomes and 
MHC class II molecules 
To explore possible implications of 
macroautophagic processing for antigen-
presentation via MHC class II molecules in 
skeletal muscle in vivo, we performed 
immunohistochemical staining in human biopsy 
tissue. We chose specimen from five sIBM 
patients, since LC3-positive macroautophagic 
processing has previously been demonstrated 
(11) and a specific immune response with 
antigen presentation in the muscle has been 
proposed for this disorder (30). Serial sections 
were stained by double-immunofluorescence 
for LC3, MHC class I and II, CD4, CD8 and by 
hematoxylin/eosin (Fig. 7A), followed by 
subsequent manual analysis of 
microphotographs with a total of 1864 muscle 
fibers. Comparable with previous results (11), 
LC3 was noted in 3.4± 2.1% of the fibers and 
MHC class II in 9.3± 4.4% (Fig. 7B). Subtype 
analysis revealed that only a minor fraction of 
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8.2± 5.9% of the MHC class II-positive fibers 
were double positive for LC3. On the other 
hand, more than 1/5 of the fibers positive for 
LC3 displayed double-labeling for MHC class 
II (22.0± 11.9%). Furthermore, serial staining 
of all MHC class II/ LC3 double positive fibers 
revealed that almost half of them had cell-to-
cell contact to immune cells positive for CD4 
(47.2%), CD8 (43.1%) or both (43.1%; data not 
shown). A subsequent co-localization analysis 
showed that 56.4% of CD4+ cells within 
inflammatory infiltrates co-stained for CD3. On 
the other hand, 36.3% of all CD3+ cells were 
double positive for CD4 (Suppl. Fig. 2). These 
data indicate that in a subset of immune cell 
surrounded muscle fibers of sIBD patients 
autophagosomes co-localize with MHC class II 
loading compartments. 
 
 
Discussion 
 
The aim of this study was to identify 
inflammatory regulators of macroautophagy in 
a tissue type that had previously been described 
to show high levels of constitutive and 
starvation-induced macroautophagy and to 
efficiently regulate this pathway during 
immune-mediated tissue damage (4) (11). We 
found that TNF-α selectively induced 
macroautophagy and co-acted with IFN-γ in 
regulating MHC class I and MHC class II 
expression in skeletal muscle cells. 
 
TNF-α is readily detectable and predominantly 
expressed in macrophages as well as in the 
endomysium and perimysium of affected 
muscle fibers from patients with polymyositis, 
dermatomyositis, and sIBM (31) (32) (27) (33) 
(20). The monokine mediates inflammation by 
increasing vascular permeability and 
endothelial cell adhesiveness as well as via 
activation of antigen presenting cells such as 
dendritic cells and macrophages which initiate 
and orchestrate adaptive immune responses. In 
addition, we identified TNF-α from complex 
mixtures of inflammatory cytokines as the 
predominant regulatory factor for 
macroautophagy in human primary myocytes. 
In line with our findings, Djavaheri-Mergny et 
al. (34) previously reported that TNF-α 
treatment induces macroautophagy in Ewing 
sarcoma cells lacking NF-κB activation. Our 
results suggest that TNF-α is one of the major 
immune regulators of macroautophagy in the 
skeletal muscle and during inflammatory 
myopathies.  
 
Cytokines such as interferons (IFNs) and 
members of the tumor necrosis factor (TNF) 
receptor-ligand family such as CD40-CD40L 
stimulation (35) (36) (37) have previously been 
reported to modulate macroautophagy, 
primarily in the context of host defense 
responses to intracellular pathogens. Restriction 
of HSV-1 infection by macroautophagy in vitro 
and in vivo was found to be dependent on the 
type I IFN signaling machinery (38) (39). Type 
II IFN has been reported to enhance 
Mycobacterium tuberculosis and Rickettsia 
conorii degradation by macroautophagy (40) 
(41), and to induce macroautophagy and 
mycobacterial clearance through immunity-
related GTPases (IRGs) in mice (42). We did 
not detect any IFN-γ mediated effect on 
macroautophagy regulation in human skeletal 
muscle cells. Thus, proinflammatory cytokines 
might affect macroautophagy differently in a 
tissue-dependent manner. Moreover, mouse 
tissues are probably more susceptible to IFN-γ 
mediated macroautophagy regulation 
mechanism because their IRGs are IFN-γ 
inducible, whereas the human IRG is not, 
suggesting that immune signals that stimulate 
macroautophagy differ between rodents and 
man.  
 
Functional implications of our findings lie in 
the augmenting effect of TNF-α on 
macroautophagy, autophagic protein 
degradation and MHC class II surface 
expression. Skeletal muscle cells lack 
constitutive MHC class II expression, but 
strongly upregulate MHC class II surface 
expression in order to present exogenous as 
well as endogenous antigens to CD4+ T cells 
following exposure to proinflammatory 
cytokines such as IFN-γ and TNF-α (21) (22) 
(23) (24). The MHC class II transactivator 
(CIITA), a transcriptional coactivator, is the 
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key intermediate that directs constitutive and 
IFN-γ inducible expression of MHC class II 
genes in professional and nonprofessional APC, 
respectively (43). It has previously been 
suggested that TNF-α augments MHC class II 
expression through a mechanism downstream 
or independent of CIITA induction in non-
professional antigen presenting cells (44) and 
that CIITA-independent MHC class II induction 
mediated by TNF-α promotes expression of 
endogenous rather than exogenous peptides in 
immune-privileged sites (45). Our data on TNF-
  mediated macroautophagy induction and 
MHC class II regulation suggest that TNF-α 
regulates MHC class II expression levels via 
delivery of autophagosome content to MIICs 
for efficient MHC class II loading and 
successive release to the cell surface. 
 
Previous studies demonstrated that inhibition of 
macroautophagy can promote or prevent 
apoptosis in the same cell depending on the 
nature of the death stimulus and subsequent 
compensatory changes, reflecting the complex 
interplay between macroautophagy and cell 
death pathways (25). We found that TNF-α 
induced upregulation of macroautophagy does 
not alter the susceptibility of skeletal muscle 
cells to TNF-R mediated apoptosis. In line with 
these observation, several studies failed to 
detect relevant apoptosis in skeletal muscle 
fibers of patients with non-myopathic muscle, 
myopathies or myositis including sIBM (46) 
suggesting that skeletal muscle fibers appear to 
be rather resistant to apoptotic cell death. 
   
To address the in vivo relevance of our 
findings, we studied muscle biopsies from 
patients with sIBM, a clinically and 
histopathologically well described entity of 
chronic muscle inflammation. In this disease, 
we previously showed that macroautophagic 
processing is present in skeletal muscle fibers 
(11). Moreover, it has been suggested that 
antigen presentation may occur in sIBM (30) as 
well as under other inflammatory conditions in 
skeletal muscle (6).  
 
Muscle biopsies from patients with sIBM 
showed that over twenty percent of fibers that 
contained autophagosomes co-stained for MHC 
class II molecules and that more than forty 
percent of double–positive fibers had contact to 
muscle-infiltrating CD4+ and CD8+ immune 
cells. The majority of CD4+ cells within 
inflammatory infiltrates co-stained for CD3. 
Although CD8+ T cells are the main component 
of inflammatory infiltrates in sIBM, a number 
of studies provided clear evidence that CD4+ T 
cells are not only present, but also clonally 
expanded in sIBM lesional tissue (47) (48) (49) 
(30) .  Since autophagy promotes MHC class II 
presentation from intracellular source proteins 
(50), it is tempting to speculate that TNF-α 
mediated macroautophagy induction and MHC 
class II upregulation could potentially maintain 
CD4+ T cell mediated (auto)-immunity in 
skeletal muscle via increased local autoantigen-
presentation. Thus, the immunohistochemical 
ex vivo analysis in skeletal muscle biopsies 
supports a functional relevance of our 
observations which can be related to human 
disease. The inflammatory component of sIBM 
is very similar to that of polymyositis and 
comprises an auto-immune attack of muscle 
fibers by T-cells, which may be activated by 
muscle fibers themselves (51). Therefore, the 
mechanisms observed here may not be 
restricted to sIBM, but could also occur in other 
inflammatory diseases of the skeletal muscle. 
 
In conclusion, our findings establish a 
mechanism through which TNF-α regulates 
both macroautophagy and MHC expression in 
skeletal myocytes and suggest that TNF-α is an 
important mediator and a potential therapeutic 
target in T cell-mediated inflammatory 
myopathies in which macroautophagy is 
involved. 
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Figure legends 
 
Figure 1. Macroautophagy is a constitutively active process in human skeletal muscle cells. 
Fig. 1A: Human rhabdomyosarcoma cells (CLL136) were stably transfected with a GFP-LC3 
reporter construct and analyzed for GFP-LC3 turnover with and without lysosomal proteolysis 
blockade due to chloroquine (CQ) treatment, 50µM for 10 hr. GFP-LC3 strongly accumulated in 
ring-shaped and cup-shaped cytosolic vesicles after 10 hr of CQ treatment (Figure 1A, right), 
suggesting that large numbers of GFP-LC3-labeled autophagosomes had formed and fused with 
lysosomes/late endosomes during the 10 hr observation period. Cells were fixed, stained with 
DAPI nucleic acid stain, and analyzed by confocal microscopy. Scale bars represent 20 µm. Fig. 
1B: Accumulation of GFP-LC3+ vesicles upon CQ treatment was dependent on macroautophagy, 
because siRNA-mediated silencing of atg12 abrogated accumulation of these vesicles. Fig. 1C: 
Similar to the skeletal muscle cell line, human primary myoblasts stained with a monoclonal 
antibody specific for LC3 showed a detectable level of constitutive macroautophagy and a 
marked accumulation of LC3+ vesicular compartments upon CQ treatment. Fig. 1D:  
Autophagosome-associated LC3 (called LC3-II) and free cytosolic LC3 (called LC3-I) can be 
distinguished by their apparent molecular weights in SDS-PAGE gel electrophoresis (16 and 18 
kDa, respectively), and thus can be quantified separately in anti-LC3 immunoblots. 
Autophagosome-associated LC3-II strongly accumulated upon CQ treatment, further 
demonstrating that LC3-II-labeled autophagosomes were constitutively degraded in endosomes 
and/or lysosomes over the course of 10 hr. In addition, inhibition of the mammalian target of 
rapamycin (mTOR) by rapamycin resulted in a substantial increase in LC3-II expression in both 
CQ treated and untreated cells. 
 
Figure 2. Cytokines enriched in supernatants with stimulatory activity on macroautophagy 
in skeletal myocytes. Fig. 2A: CCL136 muscle cells were incubated for 24 hr with supernatants 
derived from monocyte-derived dendritic cells (DC) matured with polyI:C as TLR3 agonists (left 
panel) and polyclonal T cells (T) stimulated with PHA (right panel). Accumulation of LC3-II was 
observed after treatment with DC-, but not with T cell-derived supernatants. “DC-1/2” and “T-
1/2” indicate replicates of identical conditions. Fig. 2B: Quantification of inflammatory cytokines 
enriched in stimulatory DC supernatants compared to non stimulatory T cell supernatants. IP-10 
and MCP-1 levels in DC-derived supernatants exceeded the detection range of the Luminex assay 
(not shown).  
 
Figure 3: TNF-a selectively upregulates macroautophagy in skeletal myocytes. Fig. 3A: 
TNF-α but not IFN-γ or IP-10 induces LC3-II accumulation in CCL136 muscle cells but not in 
the human keratinocyte cell line HaCat. Fig. 3B: TNF-α induces accumulation of 
autophagosomes in GFP-LC3+ transfected CCL136 muscle cells (left panel) and in untransfected 
primary myoblasts stained with a monoclonal antibody specific for LC3 (right panel). 
 
Figure 4. TNF-α  increases MHC class I and MHC class II surface expression in IFN-γ  
treated primary muscle cells. Fig. 4A: Myoblasts and HaCat cells constitutively express HLA 
class I molecules on their cell surface. MHC class I levels are upregulated by both TNF-α (50 
ng/ml) and IFN-γ (100 ng/ml) and both cytokines act synergistically on MHC class I expression 
in both cell types. Fig. 4B: IFN-γ induces HLA-DR expression in human myoblasts and HaCat 
cells, which both lack constitutive MHC class II expression. TNF-α alone does not induce HLA-
DR expression on both cell types. In contrast, addition of TNF-α to IFN-γ enhances MHC class II 
surface expression on myocytes but not HaCat cells. Diagrams display means and SEM of MHC 
expression levels from at least 4 independent experiments on myoblasts and HaCat cells, 
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respectively. Isotype controls are highlighted in grey. Numbers in each individual histogram 
represent ΔMFIs. MHC expression levels were analyzed using the paired t-test. 
 
Figure 5. Synergistic effect of TNF-α  on MHC class II regulation is restricted to cell surface 
expression levels and reversed by inhibition of macroautophagy. Displayed are changes in 
MHC expression levels in permeabilized and non-permeabilized myoblasts following 48 hours of 
cytokine exposure compared to controls. Fig. 5A: TNF-α increases HLA-DR expression induced 
by IFN-γ in myoblasts (left panel). The synergistic effect of TNF-α was not detectable in 
permeabilized myocytes (right panel). Fig. 5B: Pharmacological inhibition of macroautophagy 
with 3-MA blocked the additive effect of TNF-α  on MHC class II surface expression. Displayed 
are means and SEM from 4 (Figure 5A) and 3 (Figure 5B) independent experiments in which 
MHC expression levels were simultaneously quantified in both permeabilized vs. non-
permeabilzed and in 3-MA treated vs. non 3-MA treated myocytes. MHC expression levels were 
compared using the paired t-test. 
 
Figure 6. Resistance of Skeletal Muscle Cells to TNF-α  Induced Cell Death. Fig. 6A: TNF 
receptor (TNF-R) 1 and TNF-R2 are expressed on the surface of CCL136 muscle cells. Fig. 6B: 
CCL136 skeletal muscle cells are resistant to TNF-α treatment alone, but showed a dose-
dependent induction of cell death in the presence of TNF-α and the protein synthesis inhibitor 
CHX (1 µg/ml). Apoptotic cell death was analyzed after 24 hr by quantifying TO-PRO-3 
permeability and specific DNA fragmentation in hypodiploid cells. Fig. 6C: Macroautophagy 
function does not interfere with susceptibility to TNF-R mediated cell death in human CCL136 
muscle cells. Neither loss of macroautophagic function due to atg12-specific RNA interference or 
gain of macroautophagy function by mTOR inhibition due to rapamycin treatment (RAP, 1µg/ml) 
showed any effect on specific DNA fragmentation levels following TNF-α treatment. Fig. 6D: 
Quantification of TNF-α induced DNA fragmentation in CLL136 cells treated with or without 
atg12-specific RNA in the presence or absence of CHX averaged from 7 independent 
experiments. Specific DNA fragmentation was compared using the paired t-test. 
 
Figure 7: Muscle fibers from patients with sIBM show colocalization of autophagosomes 
and MHC class II molecules. Fig. 7A: Serial- and double-immunofluorescent staining of a 
representative skeletal muscle from a patient with sIBM with hematoxylin/ eosin (H&E) 
histochemistry and immunolabelling for LC3, MHC class I and II, CD4, and CD8. 
Photomicroscopy using a 40x objective. Fig. 7B: Quantitative double-labeling analysis of 4 
patients with sIBM stained for MHC class II and LC3. Values indicate the mean +SD of a total of 
1864 skeletal muscle fibers. 
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Table 1. Cytokines tested. 
 
 
Cytokine Concentration (ng/ml)* 
IL-12 5  
IL-15 0.5 
IL-6 1 
IL-8 5 
IP-10 5 
IL-1b 0.1 
IL-4 1 
GM-CSF 1 
TNF-α 0.5  
 
 
* Concentration in supernatants from monocyte-derived matured dendritic cell cultures quantified 
by luminex and rounded to 0.1, 0.5, 1, and 5 ng/ml. Individual cytokines were tested for their 
ability to regulate macroautophagy in skeletal myocytes with and without blockade of lysosomal 
proteolysis by chloroquine treatment. Each cytokine was tested at least three times at a 
concentration quantified in stimulatory DC-derived supernatant as well as in a 1 log higher 
concentration. MCP-1 was also found to be enriched in DC-derived cultures but not tested for 
autophagy induction. As a classical proinflammatory cytokine, IFN-γ was additionally tested at 
concentrations of 0.1 and 1 ng/ml. 
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